Feng Chai Selected Research

ARQ 197

1/2018	Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.
2/2015	Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
12/2012	Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.
12/2012	Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.
12/2011	A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors.
4/2011	Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Feng Chai Research Topics

Disease

8	Neoplasms (Cancer) 12/2018 - 04/2011
8	Infections 07/2016 - 11/2005
5	Wounds and Injuries (Trauma) 07/2021 - 03/2015
5	Thrombosis (Thrombus) 01/2021 - 08/2013
3	Phlebitis 12/2021 - 02/2015
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2018 - 04/2011
2	Essential Hypertension 01/2022 - 01/2017
2	Neointima 01/2021 - 08/2013
2	Pain (Aches) 01/2021 - 01/2019
2	Periodontal Pocket (Periodontal Pockets) 12/2020 - 01/2014
2	Bone Neoplasms (Bone Cancer) 12/2018 - 08/2014
2	Respiratory Syncytial Virus Infections 01/2016 - 01/2016
2	Hypersensitivity (Allergy) 11/2015 - 08/2013
2	Neutropenia 12/2012 - 12/2011
2	Vomiting 12/2011 - 04/2011
1	Osteoarthritis 01/2021
1	Arthritis (Polyarthritis) 01/2021
1	Periodontitis 12/2020
1	Stomach Neoplasms (Stomach Cancer) 01/2019
1	Hyperthermia 01/2019
1	Postoperative Pain 01/2019
1	Visceral Pain 01/2019
1	Osteosarcoma (Osteogenic Sarcoma) 12/2018
1	Acquired Immunodeficiency Syndrome (AIDS) 03/2017
1	Hypertension (High Blood Pressure) 01/2017
1	Inflammation (Inflammations) 06/2015
1	Melanoma (Melanoma, Malignant) 02/2015
1	Hepatocellular Carcinoma (Hepatoma) 02/2015
1	Margins of Excision 08/2014
1	Residual Neoplasm 08/2014
1	Coronary Artery Disease (Coronary Atherosclerosis) 03/2014
1	Carcinogenesis 10/2013

Drug/Important Bio-Agent (IBA)

10	Pharmaceutical PreparationsIBA 12/2021 - 10/2009
6	ARQ 197IBA 01/2018 - 04/2011
4	Anti-Bacterial Agents (Antibiotics)IBA 12/2020 - 11/2008
4	CyclodextrinsIBA 01/2019 - 11/2008
3	Vancomycin FDA LinkGeneric 12/2021 - 02/2015
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018 - 04/2011
3	ChitosanIBA 10/2017 - 03/2015
3	Proteins (Proteins, Gene)FDA Link 01/2016 - 12/2012
2	SilverIBA 07/2021 - 03/2015
2	Local Anti-Infective Agents (Antiseptics)IBA 12/2020 - 07/2019
2	EP 224283IBA 08/2020 - 08/2013
2	ChlorhexidineIBA 07/2019 - 01/2014
2	Antineoplastic Agents (Antineoplastics)IBA 12/2018 - 08/2014
2	Biocompatible Materials (Biomaterials)IBA 12/2018 - 06/2015
2	Peptides (Polypeptides)IBA 01/2016 - 10/2013
2	RNA (Ribonucleic Acid)IBA 05/2011 - 11/2005
1	Cytochrome P-450 CYP11B2 (CYP11B2)IBA 01/2022
1	Ibuprofen (Motrin)FDA LinkGeneric 07/2021
1	MetalsIBA 01/2021
1	mesoglycanIBA 01/2021
1	Formaldehyde (Formol)FDA Link 01/2021
1	Iodoacetic AcidIBA 01/2021
1	Oxygen (Dioxygen)IBA 12/2020
1	Reactive Oxygen Species (Oxygen Radicals)IBA 12/2020
1	idraparinuxIBA 08/2020
1	AvidinIBA 08/2020
1	AnticoagulantsIBA 08/2020
1	SolutionsIBA 08/2020
1	A-factor (Streptomyces)IBA 08/2020
1	polydopamineIBA 08/2020
1	Tirofiban (Aggrastat)FDA Link 08/2020
1	PolyestersIBA 01/2019
1	Ropivacaine (Naropin)FDA LinkGeneric 01/2019
1	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2018
1	Biological ProductsIBA 12/2018
1	Durapatite (Hydroxylapatite)IBA 12/2018
1	cyclodextrin polymerIBA 10/2017
1	Hemostatics (Antihemorrhagics)IBA 10/2017
1	PlasticsIBA 03/2017
1	IronIBA 01/2017
1	Type 1 Angiotensin ReceptorIBA 01/2017
1	Polylactic Acid-Polyglycolic Acid CopolymerIBA 07/2016
1	Gentamicins (Gentamicin)FDA LinkGeneric 07/2016
1	Neutralizing AntibodiesIBA 01/2016
1	AntibodiesIBA 01/2016
1	Immunoglobulin G (IgG)IBA 01/2016
1	GTP-Binding Proteins (G-Protein)IBA 01/2016
1	CytokinesIBA 01/2016
1	TitaniumIBA 06/2015
1	gentamicin AIBA 06/2015
1	PolyelectrolytesIBA 06/2015
1	Polypropylenes (Polypropylene)IBA 03/2015
1	Polyethylene (Polythene)IBA 03/2015
1	IodidesIBA 03/2015
1	Sorafenib (BAY 43-9006)FDA Link 02/2015
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2015

Therapy/Procedure

7	Therapeutics 07/2021 - 12/2011
5	Stents 01/2021 - 08/2013
5	Drug-Eluting Stents 01/2021 - 08/2013
3	Drug Therapy (Chemotherapy) 01/2019 - 01/2013
2	Injections 12/2020 - 05/2011
1	Intra-Articular Injections 01/2021
1	Herniorrhaphy 01/2019
1	Intravenous Injections 12/2018
1	Operative Surgical Procedures 07/2016
1	Orthopedic Procedures 07/2016
1	Hip Replacement Arthroplasty (Total Hip Replacement) 12/2014
1	Combined Modality Therapy 08/2014